Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biocytogen Pharmaceuticals (Beijing) Co's
Operating Income
for the
six
months ended in Dec. 2025 was €21.5 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Interest Expense for the
six
months ended in Dec. 2025 was €-4.3 Mil.
Biocytogen Pharmaceuticals (Beijing) Co's interest coverage for the quarter that ended in Dec. 2025 was 5.05.
The higher the ratio, the stronger the company's financial strength is.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biocytogen Pharmaceuticals (Beijing) Co Interest Coverage Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Biocytogen Pharmaceuticals (Beijing) Co Interest Coverage Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Interest Coverage vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Interest Coverage of 5.05 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 82% above median its historical median of 2.78. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's Interest Coverage has ranged from 1.64 to 3.93. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #327 out of 377 companies in the Biotechnology industry, placing it in the top 86.7%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Interest Coverage too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Interest Coverage of 5.05 is 82% above median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 3.93. The Biotechnology industry median Interest Coverage is 106.07. Biocytogen Pharmaceuticals (Beijing) Co's value of 5.05 is 95.2% below this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #327 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #327 out of 377 companies for Interest Coverage. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median Interest Coverage is 106.07. Biocytogen Pharmaceuticals (Beijing) Co's value of 5.05 is 95.2% below this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own Interest Coverage has ranged from 1.64 to 3.93 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 106.07, Biocytogen Pharmaceuticals (Beijing) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Interest Coverage of 5.05 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Interest Coverage is 5.05, which is 82% above median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.47, compared to a current price of €5.15 — trading 48.4% above its estimated fair value. The current Interest Coverage is 5.05, which is 82% above median its 10-year median of 2.78 and 95.2% below the Biotechnology industry median of 106.07. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Interest Coverage is 5.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.15 is trading 48.4% above its estimated GF Value™ of €3.47.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
Interest Coverage: 5.05 (82% above median its 10-year median of 2.78)
GF Value™: €3.47 vs. price of €5.15 (48.4% above fair value)
Industry Position: 95.2% below the Biotechnology median (#327 of 377)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
76GF Score
Get the complete analysis for FRA:I54
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
